Результаты поиска

A Multimodal Clinical Approach for the Treatment of Bone Metastases in Solid Tumors.

ContextBone metastasis (BM) is a frequent complication of cancer, representing the third most common site of secondary spread in solid cancers behind the lung and liver. Bone metastasis is found in up to 90% of prostate and breast cancer patients. They can cause significant complications, such as pathological fractures and paralysis of the spine, which decrease daily functioning and quality of life (QoL) and worsen prognosis. The growing life expectancy of cancer patients due to improvements in systemic therapies may further increase BM's eventuality and clinical burden in cancer patients.Evid

Совпадение в полном тексте источника
… Beta-emitting radionuclides encompass Phosphorus-32 ( 32 P), Strontium-89 ( 89 Sr), Renium-186 and -188 ( 186 Re, 188 Re), Samarium-153 ( 153 Sm), Selenium-117m ( 117m Sn), and Lutetium-177 ( 177 Lu) ( 29 ). …

CXCR4-directed endoradiotherapy with [177Lu]Pentixather added to total body irradiation for myeloablative conditioning in patients with relapsed/refractory acute myeloid leukemia.

Rationale: Despite recent advances in the targeted therapy of AML, the disease continues to have a poor prognosis. Allogeneic hematopoietic stem cell transplantation (alloSCT) remains to be the curative therapy option for fit patients with high-risk disease. Especially patients with relapsed or refractory (r/r) AML continue to have poor outcomes. Myeloablative total body irradiation (TBI) based conditioning can be used in AML patients refractory to multiple lines of standard therapy, but the optimal conditioning regimen remains unclear for patients considered to be chemotherapy- refractory. Fe

Совпадение в полном тексте источника
… Pentixather is coupled with beta minus emitting radionuclides, like 177 Lutetium or 90 Yttrium which cause localized radiation damage within a few millimeters around the binding site. …

Can 18F-NaF PET/CT before Autologous Stem Cell Transplantation Predict Survival in Multiple Myeloma?

There is an unmet need for positron emission tomography (PET) radiotracers that can image bone disease in multiple myeloma (MM) in a more sensitive and specific way than the widely used 18F-fluorodeoxyglucose (18F-FDG). Sodium fluoride (18F-NaF) is a highly sensitive tracer of bone reconstruction, evolving as an important imaging agent for the assessment of malignant bone diseases. We attempted to investigate for the first time the prognostic significance of 18F-NaF PET/CT in newly diagnosed, symptomatic MM patients planned for autologous stem cell transplantation (ASCT). Forty-seven patients

Совпадение в полном тексте источника
… homing, bone marrow retention, angiogenesis and metastasis, has shown very promising results regarding both its diagnostic performance [ 42 , 43 ] and its potential application as a theranostic agent, identifying candidates suitable for CXCR4-directed therapies with β-emitting radionuclides such as lutetium …

Meeting abstracts from the 21st European Symposium on Radiopharmacy and Radiopharmaceuticals

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Nanobodies Enhancing Cancer Visualization, Diagnosis and Therapeutics.

Worldwide, cancer is a serious health concern due to the increasing rates of incidence and mortality. Conventional cancer imaging, diagnosis and treatment practices continue to substantially contribute to the fight against cancer. However, these practices do have some risks, adverse effects and limitations, which can affect patient outcomes. Although antibodies have been developed, successfully used and proven beneficial in various oncology practices, the use of antibodies also comes with certain challenges and limitations (large in size, poor tumor penetration, high immunogenicity and a long

Совпадение в полном тексте источника
… Radionuclides (99-mTechnetium ( 99 mTc), 177-lutetium ( 177 Lu), 123-iodine ( 123 I) and 11-iodine ( 11 I)) are used in SPECT imaging, whereas positron-emitting radioisotopes (68-gallium ( 68 Ga), 124-iodine ( 124 I), zirconium-89 ( 89 Zr) and fluor-18 ( 18 F)) are used in PET imaging [ 11 ]. … antigen-binding fragment; Fv, variable fragment; scFv, single-chain Fv; CDR, complementarity-determining regions; Nbs, nanobodies; ABF, antigen-binding fragment; SPECT, single-photon emission computed tomography; PET, positron emission tomography; CT, computed tomography; 99 mTc, 99-mTechnetium; 177 Lu, 177-lutetium …

A Look to the Future: Potential Theranostic Applications in Head and Neck Tumors.

Theranostics, the practice of using a diagnostic radiopharmaceutical to guide radiotherapy with a chemically identical (or nearly identical) therapeutic radiopharmaceutical, is an exciting new field under development within the auspices of nuclear medicine. We aim to provide a narrative review of the areas of theranostics use and development which are occurring specifically in the head and neck, with attention to the therapeutic use of existing diagnostically used radiotracers such as agents that target prostate-specific membrane antigen (PSMA) and somatostatin receptors (e.g., DOTATATE deriva

Совпадение в полном тексте источника
… Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N. Engl. J. Med. 2021;385:1091–1103. doi: 10.1056/NEJMoa2107322. 41. Hofman M.S., Emmett L., Sandhu S., Iravani A., Buteau J.P., Joshua A.M., Goh J.C., Pattison D.A., Tan T.H., Kirkwood I.D., et al. …

The impact of willingness-to-pay threshold on price reduction recommendations for oncology drugs: a review of assessments conducted by the Canadian Agency for Drugs and Technologies in Health.

Since late 2020, the Canadian Agency of Drugs and Technologies in Health (CADTH) has been using a threshold of $50,000 (CAD) per quality-adjusted life-year (QALY) for both oncology and non-oncology drugs. When used for oncology products, this threshold is hypothesized to have a higher impact on the time to access these drugs in Canada. We studied the impact of price reductions on time to engagement and negotiation with the pan-Canadian Pharmaceutical Alliance for oncology drugs reviewed by CADTH between January 2020 and December 2022. Overall, 103 assessments reported data on price reductions

Совпадение в полном тексте источника
… CADTH CADTH Reimbursement Recommendation Lutetium (177Lu) Oxodotreotide (Lutathera) . ( Accessed 24 July 2023 ). https://www.cadth.ca/sites/default/files/DRR/2022/PC0284%20Lutathera%20-CADTH%20Final%20Recommendation%20Final.pdf 38498647 99. …

Management of bone metastasis with zoledronic acid: A systematic review and Bayesian network meta-analysis.

BACKGROUND: While considered the mainstay of treatment for specific bone metastases, ZA is used predominantly to treat osteolytic lesions. The purpose of this network meta-analysis is to compare ZA to other treatment options in its ability to improve specific clinical outcomes in patients with bone metastases secondary to any primary tumor. METHODS: PubMed, Embase and Web of Science were systematically searched from inception to May 5th, 2022. Keywords used were solid tumor, lung neoplasm, kidney neoplasm, breast neoplasm, prostate neoplasm, ZA and bone metastasis. Every randomized controlled

Совпадение в полном тексте источника
… Improvements in symptoms related to bone metastasis in recipients of Lutetium-177 PSMA-617 for prostate cancer. Journal of Clinical Oncology. 2022;40(6_suppl):96-. 15. Drake M.T., Clarke B.L., Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin. …

A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020.

IntroductionCancer and corresponding available treatments are associated with substantial symptoms and functional limitations. In this context, collection of patient-reported outcomes (PRO) in clinical trials gained special interest and is recommended by regulatory authorities. Within clinical trials framework, PRO may provide evidence to support medicines approval, labeling and marketing claims. This study aims to analyze the existing evidence based on PRO as part of new oncology indications receiving positive opinions issued by the European Medicines Agency (EMA) between 2017 and 2020 and to

Совпадение в полном тексте источника
… | Osimertinib | EORTC QLQ-C30 EORTC QLQ-LC13 | HRQoL,global helath status, functioning, symptoms (no difference between groups) | Double-blind RCT Ovarian Neoplasms | Niraparib | FOSI EQ-5D-5L Neuropathy Questionnaire | HRQoL (no difference between groups) | Double-blind RCT Pancreatic Neoplasms | Lutetium …

Using 5 consecutive years of NICE guidance to describe the characteristics and influencing factors on the economic evaluation of orphan oncology drugs.

OBJECTIVE: Orphan oncology drugs used in this article were defined by the type of disease treated by drugs, as drugs used to treat rare diseases with a prevalence of ≤ 500 per million people per year. In this article, our concern was to explore focus on the economic evaluation of the National Institute for Health and Care Excellence (NICE), when orphan oncology drugs were appraised for reimbursement, and provide advice and suggestions to decision-makers. METHODS: A retrospective study was used in this study. Thirty guidance were gathered as our subject by NICE from 2016 to 2020, excluded drug

Совпадение в полном тексте источника
… The three orphan oncology drugs appraised by MTA were lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumors, cabozantinib for treating medullary thyroid cancer, and lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine, all …

Bone metastases in pheochromocytomas and paragangliomas: a narrative review of presentation, diagnosis and management.

BACKGROUND: Bone metastases (BM) are a frequent and clinically relevant manifestation in patients with metastatic pheochromocytomas and paragangliomas (mPPGL). OBJECTIVE: This narrative review aims to summarize the current understanding of the pathophysiology, epidemiology, clinical presentation, complications, quality of life impact, and management of BM in mPPGL. SUMMARY: Bone and lymph nodes are among the most common metastatic sites in malignant PPGL. Skeletal involvement-particularly in paragangliomas-is associated with a high incidence of skeletal-related events (SREs), including patho

Совпадение в полном тексте источника
… Radionuclide therapies Peptide receptor radionuclide therapy PRRT with Lutetium-177-DOTATATE ( 177 Lu-DOTATATE) has demonstrated significant clinical efficacy in patients with metastatic NETs involving the skeleton. … Although BM in mPPGL have not been specifically studied, patients with moderately progressive mPPGL expressing SSTRs may benefit from PRRT with lutetium 177 Lu- DOTATATE. This therapy has demonstrated clinical and biochemical efficacy in functional mPPGL, with a favorable safety profile. …

Therapeutic potential of cytokine-induced killer cell therapy for renal cell carcinoma and prostate cancer.

Renal cell carcinoma (RCC) and prostate cancer (PCa) are among the most prevalent and therapeutically challenging malignancies of the genitourinary system, particularly in advanced or metastatic stages. For advanced/metastatic RCC, targeted agents such as tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) have improved progression-free and overall survival. For metastatic castration-sensitive PCa, androgen deprivation therapy (ADT) combined androgen receptor pathway inhibitors (ARPIs) with or without chemotherapy remains the standard of care. Despite these advances, ther

Совпадение в полном тексте источника
… Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. …

Abstracts

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Early assessment of efficacy and toxicity Indraja Dev, Venkatesh Rangarajan, Ameya Puranik, Nilendu Purandare, Sneha Shah, Archi Agrawal, Sayak Choudhury, Suchismita Ghosh Department of Nuclear Medicine, ACTREC, Tata Memorial Center, Mumbai, Maharashtra, India Introduction: PRRT with Intravenous Lutetium …

Biomarker-Driven Approaches to Bone Metastases: From Molecular Mechanisms to Clinical Applications.

Bone metastases represent a critical complication in oncology, frequently indicating advanced malignancy and substantially reducing patient quality of life. This review provides a comprehensive analysis of the complex interactions between tumor cells and the bone microenvironment, emphasizing the relevance of the "seed and soil" hypothesis, the RANK/RANKL/OPG signaling axis, and Wnt signaling pathways that collectively drive metastatic progression. The molecular and cellular mechanisms underlying the formation of osteolytic and osteoblastic lesions are examined in detail, with a particular foc

Совпадение в полном тексте источника
… Lutetium-177 (Lu-PSMA-617) is a beta-emitting radionuclide therapy that targets bone metastases. Beta radiation can be delivered straight to tumor cells expressing PSMA using this focused strategy. …

ImmunoPET in Multiple Myeloma-What? So What? Now What?

Despite constant progress over the past three decades, multiple myeloma (MM) is still an incurable disease, and the identification of new biomarkers to better select patients and adapt therapy is more relevant than ever. Recently, the introduction of therapeutic monoclonal antibodies (mAbs) (including direct-targeting mAbs and immune checkpoint inhibitors) appears to have changed the paradigm of MM management, emphasizing the opportunity to cure MM patients through an immunotherapeutic approach. In this context, immuno-positron emission tomography (immunoPET), combining the high sensitivity an

Совпадение в полном тексте источника
… Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model Front. Med. 2015 2 553 10.3389/fmed.2015.00076 PMC4631990 26582128 110. Gouard S. Chalopin B. Saï-Maurel C. Guérard F. Navarro L. Gestin J.-F. …

Прогресс в развитии лекарственных средств на основе пептида: платформы для доставки, терапевтические средства и вакцины.

Успешное утверждение лекарств на основе пептида можно отнести на счет совместных усилий по целому ряду дисциплин. Интеграция новых методов разработки и синтеза лекарственных средств, отображение библиотечных технологий, систем доставки, достижений в области биоинженерии и искусственного интеллекта в значительной степени ускорила разработку новейших лекарств на основе пептида, эффективно устраняя препятствия, связанные с их характером, такие, как быстрое обезвреживание и деградация, необходимость субколичественной инъекции, ведущей к усилению дискомфорта пациентов, и в конечном итоге продвигая

Совпадение в полном тексте источника
… Servier 18 Lutetium Lu 177 dotatate Lutathera ® 2018 Radioligand Therapeutic Agent Somatostatin receptor Treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) i.v . … IDORSIA 34 Lutetium 177Lu vipivotide tetraxetan Pluvicto ® 2022 Radioligand Therapeutic Agent PSMA prostate cancer-specific membrane antigen Metastatic denervation-resistant prostate cancer i.v . AAA USA NOVARTIS 35 Tirzepatide Zepbound ® 2022 GIP and GLP-1 dual agonists GIPR&GLP-1R T2DM s.c . …

The Power of Phytochemicals Combination in Cancer Chemoprevention.

Conventional therapies for cancer treatment have posed many challenges, including toxicity, multidrug resistance and economic expenses. In contrast, complementary alternative medicine (CAM), employing phytochemicals have recently received increased attention owing to their capability to modulate a myriad of molecular mechanisms with a less toxic effect. Increasing evidence from preclinical and clinical studies suggest that phytochemicals can favorably modulate several signaling pathways involved in cancer development and progression. Combinations of phytochemicals promote cell death, inhibit c

Совпадение в полном тексте источника
… Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. Journal of Medical Radiation Sciences. 2017;64:52–60. doi: 10.1002/jmrs.227. 13. R. Od, Oliveira, L.C. de Santa Maria, G, Barratt. …

RNA therapeutics in targeting G protein-coupled receptors: Recent advances and challenges.

G protein-coupled receptors (GPCRs) are the major targets of existing drugs for a plethora of human diseases and dominate the pharmaceutical market. However, over 50% of the GPCRs remain undruggable. To pursue a breakthrough and overcome this situation, there is significant clinical research for developing RNA-based drugs specifically targeting GPCRs, but none has been approved so far. RNA therapeutics represent a unique and promising approach to selectively targeting previously undruggable targets, including undruggable GPCRs. However, the development of RNA therapeutics faces significant cha

Совпадение в полном тексте источника
… Ireland) CHRM1-CHRM5 A, acetylcholine chronic obstructive pulmonary disease 2018 Tolvaptan Jynarque V2R A, vasopressin and oxytocin adults at risk of rapidly progressing autosomal dominant polycystic kidney disease 2018 Lofexidine hydrochloride Lucemyra α 2 -AR A, adrenaline opiate withdrawal 2018 Lutetium … acetylcholine | chronic obstructive pulmonary disease | 2018 Tolvaptan | Jynarque | V2R | A, vasopressin and oxytocin | adults at risk of rapidly progressing autosomal dominant polycystic kidney disease | 2018 Lofexidine hydrochloride | Lucemyra | α 2 -AR | A, adrenaline | opiate withdrawal | 2018 Lutetium …

Cancer treatment using peptides: current therapies and future prospects.

This paper discusses the role of peptides in cancer therapy with special emphasis on peptide drugs which are already approved and those in clinical trials. The potential of peptides in cancer treatment is evident from a variety of different strategies that are available to address the progression of tumor growth and propagation of the disease. Use of peptides that can directly target cancer cells without affecting normal cells (targeted therapy) is evolving as an alternate strategy to conventional chemotherapy. Peptide can be utilized directly as a cytotoxic agent through various mechanisms or

Совпадение в полном тексте источника
… imaging in human breast carcinoma versus immunohistochemistry Journal of Nuclear Medicine 2008 49 2 260 264 2-s2.0-38949192477 18199617 10.2967/jnumed.107.047167 54 Zhang H Chen J Waldherr C Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with Indium-111, Lutetium …

Декодирование GPCR, сигнализирующее перепрограммирование рака: молекулярные механизмы и терапевтические последствия.

G белковые рецепторы (GPCR) представляют собой крупнейшую мембранную группу рецепторов в геноме человека и служат ключевыми регуляторами клеточного сигнала, гомеостаза и фармакологической реакции. Помимо их классической роли в посредничестве внеклеточной стимуляции по зависящим от G-протеина и независимым путям, которые играют ключевую роль при помощи GPCR сигнальных путей, включая CAMP-PKA/EPAC, IP3/PLC, PI3K/Akt/mTOR и ERK/MAPK cascades, в вождении онкогенного распространения, апоптоза и метастаза. Кроме того, ГПХР замешаны в опухоли с помощью различных молекулярных механизмов, в рамках кото

Совпадение в полном тексте источника
… (ii) In the therapeutic phase, the same targeting molecule is labeled with a beta-emitting radionuclide, such as lutetium-177 or yttrium-90. … While using PentixaTher 1 ⁷⁷Lu (Lutetium-177) or ⁹⁰Y (Yttrium-90) labeled, the compound becomes a treatment agent. …